BioXtal
![]() |
|||||||||||
BioXtal is a company that has been providing R&D services to the pharmaceutical industry since its inception in 1998. BioXtal has continually expanded its offerings in the field of structural biology. Their services include protein structure analysis, production of proteins, membrane extracts, and Nanobodies. Notably, in January 2024, BioXtal launched a partnership with APHP to introduce the SNPXplex, a reagent for identity Monitoring. This reagent enhances the security of NGS and genomic analyses for personalized medicine. For a deeper understanding of protein structures, BioXtal’s cutting-edge techniques can help you unravel the mysteries of protein function and design new drugs. Learn More:
Website: https://www.bioxtal.com/ |
Identity monitoring kit for NGS : SNPXplex
Identity monitoring is a discipline linked to identity management in the field of healthcare and patient safety. It aims to guarantee the accuracy and integrity of personal data held by patients, healthcare professionals and other healthcare system stakeholders.
The main aim of identity monitoring is to prevent identification errors, which can have serious consequences in the healthcare sector. This includes errors linked to the identification of patients, healthcare professionals, medicines, biological samples, etc.
The measures implemented as part of identity monitoring often include the standardization of identification procedures, the use of cutting-edge technologies such as barcodes and patient identification wristbands, and staff training to ensure secure care and correct identity management at every stage of healthcare.
In this context, BIOXTAL, in partnership with the APHP, is offering an identity monitoring reagent to secure personalized medicine analyses using NGS and genomics.
The SNPXplex reagent
As a result of an agreement with the APHP, BIOXTAL exclusively produces and markets the SNPXplex identity monitoring reagent. The SNPXplex reagent is used to secure NGS and genomic analyses in personalized medicine.
The test principle is simple. It involves identifying each patient on the basis of 15 specially selected SNPs - in a way that is totally uncorrelated with primary NGS analyses, and by means of a simple PCR followed by analysis on a capillary sequencer - to validate that the NGS analysis results obtained do indeed correspond to each patient concerned, and that the clinician will be able to make the right diagnosis.
The 15 SNPs detected by the SNPXplex reagent have been specially selected to cover non-pathogenic genes, thus avoiding any bias linked to particular patient populations.
Resultados de su búsqueda : 2 Producto encontrado
Refine su búsqueda :
- kit 2